% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • terry_insm terry_insm Jul 9, 2013 11:46 AM Flag

    Canaccord - what they didn't say

    Take note that all the analysts who all got it wrong raised their target, so CYA is in full swing.
    As posted Insmed dropped the filing in the US on compelling data since the data wasnt compelling.
    Cannacord thinks the NTM results are now 1st quarter 2014, which makes perfect business sense for those analysts with tax loss selling - )
    How Cannacord could say invitro work or these results would support anything is unbelievable...
    Approval mentioned for Europe...I agree, what I disagree is that the drug gets the EU agencys seal of good coverage.
    but this one
    "While there are optical imbalances in Arikace’s severe adverse events, INSM indicated
    there is no kidney or ototox signal, our main concern. We look forward to
    reviewing more details at medical meetings/in publication later this year."

    Ill let investors of bio and the fact the prelininary adverse data was not good decide.
    Good Luck

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.19-0.03(-0.23%)11:09 AMEDT